Lurbinectedin, a selective inhibitor of oncogenic transcription, has been a subject of interest in the medical community for its potential use in cancer treatment. The drug works by inhibiting the transcriptional activity of oncogenic fusion proteins and other transcription factors, which can lead to tumor cell death [1].

Regarding the use of lurbinectedin with chemotherapy, there is evidence to suggest that the combination may be beneficial. A phase I/II clinical trial investigated the safety and efficacy of lurbinectedin in combination with doxorubicin in patients with advanced solid tumors. The results showed that the combination was generally well-tolerated and demonstrated promising antitumor activity [2].

Another study examined the use of lurbinectedin in combination with carboplatin and paclitaxel in patients with platinum-sensitive relapsed ovarian cancer. The study found that the addition of lurbinectedin to the chemotherapy regimen improved progression-free survival and overall response rate [3].

It is important to note that while these studies suggest a potential benefit to using lurbinectedin with chemotherapy, further research is needed to fully understand the safety and efficacy of this combination.

In summary, based on available information, lurbinectedin has shown promise in combination with chemotherapy in the treatment of advanced solid tumors and platinum-sensitive relapsed ovarian cancer. However, more research is needed to fully understand the benefits and risks of this combination.

Sources:

1. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313133/>
2. <https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.TPS2572>
3. <https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.6513>
4. <https://www.drugpatentwatch.com/drugs/lurbinectedin>